These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 25719984)

  • 1. RELATIONSHIP BETWEEN VISUAL PROGNOSIS AND DELAY OF INTRAVITREAL INJECTION OF RANIBIZUMAB WHEN TREATING AGE-RELATED MACULAR DEGENERATION.
    Takahashi H; Ohkubo Y; Sato A; Takezawa M; Fujino Y; Yanagi Y; Kawashima H
    Retina; 2015 Jul; 35(7):1331-8. PubMed ID: 25719984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity.
    Saito M; Iida T; Kano M
    Retina; 2012 Jul; 32(7):1250-9. PubMed ID: 22446886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal anti-vascular endothelial growth factor for typical exudative age-related macular degeneration in eyes with good baseline visual acuity.
    Chang YS; Han JI; Yoo SJ; Lew YJ; Kim JH
    Korean J Ophthalmol; 2014 Dec; 28(6):466-72. PubMed ID: 25435749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visual outcomes in relation to time to treatment in neovascular age-related macular degeneration.
    Rasmussen A; Brandi S; Fuchs J; Hansen LH; Lund-Andersen H; Sander B; Larsen M
    Acta Ophthalmol; 2015 Nov; 93(7):616-20. PubMed ID: 26073051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TEN-YEAR FOLLOW-UP OF PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS.
    Starr MR; Kung FF; Mejia CA; Bui YT; Bakri SJ
    Retina; 2020 Sep; 40(9):1665-1672. PubMed ID: 31725524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of intravitreal ranibizumab in phakic and pseudophakic neovascular age-related macular degeneration patients with good baseline visual acuity.
    Ozkaya A; Alkin Z; Yazici AT; Demirok A
    Retina; 2014 May; 34(5):853-9. PubMed ID: 24141904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes.
    Baek JS; Cho HJ; Cho SW; Kim CG; Kim JW
    Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of posterior vitreous detachment on outcome of anti-vascular endothelial growth factor treatment in age-related macular degeneration.
    Üney GÖ; Ünlü N; Acar MA; Hazirolan D; Altiparmak UE; Yalniz-Akkaya Z; Örnek F
    Retina; 2014 Jan; 34(1):32-7. PubMed ID: 23751943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SWITCHING TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION FROM BEVACIZUMAB TO RANIBIZUMAB: Who is Likely to Benefit From the Switch?
    Moisseiev E; Katz G; Moisseiev J; Loewenstein A; Goldstein M; Lomnicky Y; Abend Y; Treister G; Goldenberg D; Levkovitch-Verbin H
    Retina; 2015 Jul; 35(7):1323-30. PubMed ID: 26102434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dexamethasone intravitreal implant as adjunct therapy for patients with wet age-related macular degeneration with incomplete response to ranibizumab.
    Calvo P; Ferreras A; Al Adel F; Wang Y; Brent MH
    Br J Ophthalmol; 2015 Jun; 99(6):723-6. PubMed ID: 25425713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
    Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CHANGES IN VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB IN DAILY CLINICAL PRACTICE: The TWIN Study.
    Souied EH; Oubraham H; Mimoun G; Cohen SY; Quere S; Derveloy A;
    Retina; 2015 Sep; 35(9):1743-9. PubMed ID: 25901835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration.
    Gomi F; Sawa M; Tsujikawa M; Nishida K
    Retina; 2012 Oct; 32(9):1804-10. PubMed ID: 22718152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Choroidal blood flow after the first intravitreal ranibizumab injection in neovascular age-related macular degeneration patients.
    Mottet B; Aptel F; Geiser MH; Hera R; Zhou T; Almanjoumi A; Vinh V; Chiquet C
    Acta Ophthalmol; 2018 Nov; 96(7):e783-e788. PubMed ID: 30203609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time to first treatment: The significance of early treatment of exudative age-related macular degeneration.
    Rauch R; Weingessel B; Maca SM; Vecsei-Marlovits PV
    Retina; 2012 Jul; 32(7):1260-4. PubMed ID: 22186738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.
    Kang HM; Kwon HJ; Yi JH; Lee CS; Lee SC
    Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rate of vision loss in neovascular age-related macular degeneration explored.
    Real JP; Granero GE; De Santis MO; Juarez CP; Palma SD; Kelly SP; Luna JD
    Graefes Arch Clin Exp Ophthalmol; 2015 Nov; 253(11):1859-65. PubMed ID: 25491161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultrasound assessment of ocular vascular effects of repeated intravitreal injections of ranibizumab for wet age-related macular degeneration.
    Bonnin P; Pournaras JA; Makowiecka K; Krivosic V; Kedra AW; Le Gargasson JF; Gaudric A; Levy BI; Cohen YS; Tadayoni R; Massin P
    Acta Ophthalmol; 2014 Aug; 92(5):e382-7. PubMed ID: 25043792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of fellow eye visual acuity on visual acuity of study eyes receiving ranibizumab for age-related macular degeneration.
    Zweifel SA; Saroj N; Shapiro H; Freund KB
    Retina; 2012 Jul; 32(7):1243-9. PubMed ID: 22466461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.